Bristol Myers Squibb will become responsible for the development and any marketing of DF6002 and its related products worldwide ... it plans to advance R&D in oncology and haematology and is ...

The U.S. Food and Drug Administration said on Friday that it has approved an injectable version of Bristol Myers Squibb's blockbuster cancer drug, Opdivo.

Bristol Myers Squibb is doubling down on a partnership with Medidata, signing a multiyear agreement to continue using the ...

Gilead has poached an oncology research leader from Bristol-Myers Squibb, appointing Michael ... discovery and development of eight marketed products and the advancement of more than 30 compounds ...

BMS-986484 is under clinical development by Bristol-Myers Squibb and currently in Phase I for Non-Small Cell Lung Cancer.

Fangzhou Inc, a pioneer in internet healthcare solutions, announced a strategic alliance with Bristol Myers Squibb (BMS) China, a global biopharmaceutical company with a robust research and ...